The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism
Open accessAbstract
BACKGROUND: HIV protease inhibitor (PI) therapy results in the rapid selection of drug resistant viral variants harbouring one or two substitutions in the viral protease. To combat PI resistance development, two approaches have been developed. The first is to increase the level of PI in the plasma of the patient, and the second is to develop novel PI with high potency against the known PI-resistant HIV protease variants. Both approaches share the requirement for a considerable increase in the number of protease mutations to lead to clinical resistance, thereby increasing the genetic barrier. We investigated whether HIV could yet again find a way to become less susceptible to these novel inhibitors. METHODS AND FINDINGS: We have performed in vitro selection experiments using a novel PI with an increased genetic barrier (RO033-4649) and demonstrated selection of three viruses 4- to 8-fold resistant to all PI compared to wild type. These PI-resistant viruses did not have a single substitution in the viral protease. Full genomic sequencing revealed the presence of NC/p1 cleavage site substitutions in the viral Gag polyprotein (K436E and/or I437T/V) in all three resistant viruses. These changes, when introduced in a reference strain, conferred PI resistance. The mechanism leading to PI resistance is enhancement of the processing efficiency of the altered substrate by wild-type protease. Analysis of genotypic and phenotypic resistance profiles of 28,000 clinical isolates demonstrated the presence of these NC/p1 cleavage site mutations in some clinical samples (codon 431 substitutions in 13%, codon 436 substitutions in 8%, and codon 437 substitutions in 10%). Moreover, these cleavage site substitutions were highly significantly associated with reduced susceptibility to PI in clinical isolates lacking primary protease mutations. Furthermore, we used data from a clinical trial (NARVAL, ANRS 088) to demonstrate that these NC/p1 cleavage site changes are associated with virological failure during PI therapy. CONCLUSIONS: HIV can use an alternative mechanism to become resistant to PI by changing the substrate instead of the protease. Further studies are required to determine to what extent cleavage site mutations may explain virological failure during PI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wiegers, K., Rutter, G., Kottler, H., Tessmer, U., Hohenberg, H., & Kräusslich, H.-G. (1998) · Journal of Virology · doi:10.1128/jvi.72.4.2846-2854.1998 · Cited by 336
Cited by
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance
Wensing, A. M. J., van Maarseveen, N. M., & Nijhuis, M. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.003 · Cited by 339
Self-citationMoses, T., Pollier, J., Thevelein, J. M., & Goossens, A. (2013) · New Phytologist · doi:10.1111/nph.12325 · Cited by 245
Retroviral proteases and their roles in virion maturation
Konvalinka, J., Kräusslich, H.-G., & Müller, B. (2015) · Virology · doi:10.1016/j.virol.2015.03.021 · Cited by 148
Self-citationFull-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays
Gupta, R. K., Kohli, A., McCormick, A. L., Towers, G. J., Pillay, D., & Parry, C. M. (2010) · AIDS · doi:10.1097/qad.0b013e3283398216 · Cited by 71
Metadata
- Authors
- Nijhuis, M., van Maarseveen, N. M., Lastere, S., Schipper, P., Coakley, E., Glass, B., Rovenska, M., de Jong, D., Chappey, C., Goedegebuure, I. W., Heilek-Snyder, G., Dulude, D., Cammack, N., Brakier-Gingras, L., Konvalinka, J., Parkin, N., Kräusslich, H.-G., Brun-Vezinet, F., & Boucher, C. A. B.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-01-16
- Volume
- 4
- Issue
- 1
- Pages
- e36
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2017953463
- Cited by
- 168
- References
- 1
- FWCI
- 12.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism. https://app.cochat.ai/papers/10.1371/journal.pmed.0040036
- The paper
- Nijhuis, M., van Maarseveen, N. M., Lastere, S., Schipper, P., Coakley, E., Glass, B., Rovenska, M., de Jong, D., Chappey, C., Goedegebuure, I. W., Heilek-Snyder, G., Dulude, D., Cammack, N., Brakier-Gingras, L., Konvalinka, J., Parkin, N., Kräusslich, H.-G., Brun-Vezinet, F., & Boucher, C. A. B. (2007). A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism. PLoS Medicine. https://doi.org/10.1371/journal.pmed.0040036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.